Last reviewed · How we verify
Eraxis (ANIDULAFUNGIN)
Eraxis works by inhibiting the synthesis of beta-1,3-D-glucan, a critical component of the fungal cell wall.
At a glance
| Generic name | ANIDULAFUNGIN |
|---|---|
| Sponsor | Vicuron Holdings |
| Drug class | Echinocandin Antifungal [EPC] |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2006 |
Mechanism of action
Anidulafungin is an anti-fungal drug [see Microbiology (12.4)].
Approved indications
- Candida Peritonitis
- Candidemia
- Candidiasis of the esophagus
- Disseminated candidiasis
- Intra-Abdominal Candida Abscess
Common side effects
- Hypokalemia
- Nausea
- Diarrhea
- Vomiting
- Pyrexia
- Hypotension
- Insomnia
- Anemia
- Headache
- Dyspepsia
- Oral candidiasis
- Abdominal pain
Key clinical trials
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (PHASE3)
- Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.
- A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
- Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
- Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients
- Azole-echinocandin Combination Therapy for Invasive Aspergillosis (PHASE3)
- Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (PHASE2)
- Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eraxis CI brief — competitive landscape report
- Eraxis updates RSS · CI watch RSS
- Vicuron Holdings portfolio CI